Oncology Clinical Trials in Fargo, ND
As of June 2026, 55 paid clinical trials are recruiting for Oncology in Fargo, North Dakota. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
55 clinical trials for Oncology
·Clear filters·↓ Download CSVKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
E-Mindfulness Approaches for Living After Breast Cancer
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practices
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Mobile Health for Adherence in Breast Cancer Patients
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
About research studies in Fargo
Fargo has approximately 206 recruiting research studies across a wide range of therapeutic areas. North Dakota hosts a diverse network of universities, academic medical centers, and community hospitals that run clinical trials across oncology, cardiology, neurology, and many other therapeutic areas.
Top Research Study Locations in Fargo
Researchers run research studies in Fargo, ND at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Sanford Broadway Medical Center | Stage IV Lung Cancer AJCC v8, Malignant Solid Neoplasm, Stage IIIB Lung Cancer AJCC v8 | 91 |
| Sanford Roger Maris Cancer Center | Stage IV Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | 72 |
| Essentia Health Cancer Center-South University Clinic | Anatomic Stage II Breast Cancer AJCC v8, Breast Cancer, Lung Non-Small Cell Carcinoma | 48 |
| Sanford Medical Center Fargo | Stage IIIB Lung Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Solid Neoplasm | 20 |
| Sanford South University Medical Center | Stage IIIB Lung Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Solid Neoplasm | 20 |
| Southpointe-Sanford Medical Center Fargo | Stage IIIB Lung Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Solid Neoplasm | 18 |
| Sanford Health | Pregnancy, ACL Injury, Advanced Cancer | 9 |
| Sanford Fargo Medical Center | Breast Neoplasms, Extensive-Stage Small Cell Lung Cancer, Multiple Myeloma | 7 |
| Sanford Fargo Medical Center-Roger Maris Cancer Center | Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer | 7 |
| Lillestol Research | Chronic Pain, Osteoarthritis, Knee, Chronic Low-back Pain | 6 |
| Lillestol Research LLC | Obesity, Cardiovascular Disease, Obstructive Sleep Apnoea | 3 |
| Red River Research Partners | Atopic Dermatitis (AD), Hidradenitis Suppurativa, NonSegmental Vitiligo | 3 |
| Red River Research Partners, LLC | Atopic, Atopic Dermatitis, Dermatitis | 3 |
| Lillestol Research, LLC | Cardiovascular Diseases, Chronic Idiopathic Constipation (CIC), Diabetes Mellitus, Type 2 | 3 |
| AXIS Clinicals - Fargo | Prurigo Nodularis, Pruritus, Dermatitis Atopic | 3 |
| Bergstrom Eye Research | Age Related Cataracts, Cataract | 2 |
| Sanford Fargo | Head and Neck Squamous Cell Carcinoma, Moderate Aortic Valve Stenosis | 2 |
| Sanford Medical Center | Lumbar Spinal Stenosis, Open tíbia Fracture | 2 |
| Vance Thompson Vision | Astigmatism, Myopia, Pseudoexfoliation Glaucoma | 2 |
| Plains Medical Clinic | Ulcerative Colitis, Crohn's Disease | 2 |
| Sanford Health Roger Maris Cancer Center | Malignant Neoplasm, Diffuse Large B-Cell Lymphoma | 2 |
| Sanford Health - Fargo | Acute Myocardial Infarction (AMI), Cardiovascular Risk | 1 |
| Axis Clincals USA/ Red River Research Patners. LLC | Psoriasis | 1 |
| Bergstrom Eye Research LLC | Age-Related Macular Degeneration | 1 |
| CBCC Global Research Site:003 | Age-related Wet Macular Degeneration | 1 |
Active & Upcoming Studies in Fargo (2026)
Recruiting trials in Fargo grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (122 active studies)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations · Phase 3 · SWOG Cancer Research Network
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · Alliance for Clinical Trials in Oncology
Diabetes & metabolic (9 active studies)
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight · Phase 3 · Novo Nordisk A/S
- AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea · Phase 3 · Novo Nordisk A/S
Neurology & pain (8 active studies)
- A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain · Phase 2 · Eli Lilly and Company
- A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain · Phase 2 · Eli Lilly and Company
Eye & vision (6 active studies)
- A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated · Phase 1, Phase 2 · Boehringer Ingelheim
- The Safety and Efficacy of Direct SLT in Pseudoexfoliation Glaucoma · Vance Thompson Vision
Cardiovascular (3 active studies)
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease · Phase 3 · Alnylam Pharmaceuticals
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease · Phase 3 · Boehringer Ingelheim
Mental health & behavior (2 active studies)
- E-Mindfulness Approaches for Living After Breast Cancer · Phase 3 · NRG Oncology
- Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program · Phase 3 · Alliance for Clinical Trials in Oncology
Vaccines (1 active study)
Common conditions studied in Fargo
- Stage IV Lung Cancer AJCC v8 (7 active studies). Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens.
- Breast Cancer (5 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Malignant Solid Neoplasm (5 active studies). Recruiting Malignant Solid Neoplasm studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Melanoma (5 active studies). Melanoma trials test immune checkpoint inhibitors, adoptive cell therapies, and BRAF/MEK targeted combinations in both early and metastatic disease.
- Stage IIIB Lung Cancer AJCC v8 (5 active studies). Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens.
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
Leading research sponsors in Fargo
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- Children's Oncology Group
- NRG Oncology
Local regulations and guidelines
Clinical trials in North Dakota are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. North Dakota research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Fargo. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Fargo
Hipa.ai aggregates every recruiting study in Fargo from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Fargo?
There are approximately 206 recruiting clinical trials in Fargo, North Dakota listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Fargo pay participants?
Most recruiting trials in Fargo compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Fargo?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Fargo?
The most common conditions under active study in Fargo include Stage IV Lung Cancer AJCC v8 (7), Breast Cancer (5), Malignant Solid Neoplasm (5), Melanoma (5), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Fargo?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Fargo on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Fargo?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Fargo?
Recruiting research sites in Fargo include Sanford Broadway Medical Center, Sanford Roger Maris Cancer Center, Essentia Health Cancer Center-South University Clinic, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Fargo right now?
The largest active categories in Fargo are Cancer & tumors (122), Diabetes & metabolic (9), Neurology & pain (8). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.